Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
How do you approach tapering of tocilizumab used for a history of GCA with vision loss?
Related Questions
How would you approach a male in his 60s with bilateral optic perineuritis/neuritis on MRI, steroid-responsive bilateral jaw pain, normal ESR/CRP, negative temporal artery biopsy, and elevated IgG4?
What biologic or conventional/synthetic DMARD would you use as a steroid sparing agent in a patient with GCA and a history of diverticulitis?
In patients with livedoid vasculitis and chronic venous insufficiency on rivaroxaban, what therapeutic strategies—beyond compression and topical care—are safe and effective for controlling pain, ulceration, and edema?
What strategies do you use when initiating treatment for complex livedoid vasculitis in a patient you cannot follow long-term, especially when therapy is limited to conservative measures due to medication contraindications?
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?
How do you differentiate fibromuscular dysplasia from PAN / abdominal vasculitis?
Do you always pursue biopsy confirmation before diagnosing IgA vasculitis?
Would you consider upadacitinib for GCA in a patient with history of breast cancer now in remission?
What is your approach to treating IgA nephropathy in patients who also have IgA vasculitis?
How would you approach failure of maintenance therapy (Azathioprine) for PR3 positive, c-ANCA positive, pulmonary–renal vasculitis previously induced with cyclophosphamide, with a history of anaphylaxis to rituximab?
